http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
증례 : 호흡기 ; 심전도상 허혈성 심질환 소견을 보인 폐암의 심장 전이 1예
전세용 ( Se Yong Jeon ),김민수 ( Min Soo Kim ),안세한 ( Se Han Ahn ),국은희 ( Eun Hee Kook ),윤정호 ( Jung Ho Yoon ),한민성 ( Min Sung Han ),이재철 ( Jae Cheol Lee ) 대한내과학회 2009 대한내과학회지 Vol.77 No.2
폐암의 심장 전이는 비특이적인 증상과 징후로 의심하지 않으면 임상적으로 발견하기가 쉽지 않다. 허혈성 심질환 때 생기는 심전도와 유사한 변화를 보이는 경우가 많고 실제 관상동맥에 문제가 동반되는 일도 있기 때문에 주의를 요한다. 폐암의 심근 전이로 인한 심전도 변화를 보인 환자를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Metastatic tumors to the myocardium proper are uncommon and difficult to diagnose because they have nonspecific signs and symptoms. Electrocardiogram (ECG) changes mimicking ischemic heart disease often develop when non-conducting tumor tissue replaces cardiac muscle. Hence, a high level of suspicion is required to differentiate ECG changes caused by myocardial metastasis from those caused by coronary heart disease in cancer patients. We describe a case of primary lung cancer with myocardial metastasis that showed diffuse ST segment elevation and T wave inversion on the ECG, with a relevant literature review. (Korean J 77:232-235, 2009)
5 kWh급 플라이휠 에너지 저장 시스템용 전자석 베어링의 성능평가
전세용(S. Y. Jung),한상철(S. C. Han),한영희(Y. H. Han),박병준(B. J. Park),이정필(J. P. Lee),박병철(B. C. Park) 대한전기학회 2010 정보 및 제어 심포지엄 논문집 Vol.2010 No.10
플라이휠 에너지 저장 시스템(FESS, Flywheel Energy Storage System)은 전기를 이용하여 플라이휠을 회전시켜 전기 에너지를 운동 에너지로 저장하는 기계식 축전지이다. 플라이휠 에너지 저장 시스템은 무접촉식 전자석 베어링, 고에너지밀도의 복합재 플라이휠, 고효율 전동/발전기 그리고 공기저항을 최화할 수 있는 진공챔버로 구성되어 있다. 특히 무접촉식 전자석 베어링은 플라이휠의 진동제어를 통하여 시스템의 효율과 안정성에 중요한 역할을 한다. 본 논문에서는 5 kWh급 플라이휠 에너지 저장 시스템용 전자석 베어링의 성능을 0.95 kWh급 스틸 로터를 이용하여 평가하였다. 0.95 kWh급 스틸 로터는 에너지 저장부인 복합재 휠부분을 제외한 나마지 사양이 5 kWh급 플라이휠과 동일하다. 5 kWh급 플라이휠보다 가속 및 감속이 더 용이한 0.95 kWh급 스틸 로터를 이용하여 운전속도인 9,000 rpm - 18,000 rpm에서 고속회전 운전하여 여러 주파수 대역에서 발생하는 진폭 등을 확인하여 진동제어를 담당하고 있는 무접촉식 전자석 베어링의 성능을 평가하고 그 결과를 5 kWh급 플라이휠 에너지 저장 시스템 운전에 적용하였다.
박정선,김선호,전세용 한국경영과학회 1996 한국경영과학회 학술대회논문집 Vol.- No.1
CALS (Commerce At the Light Speed) is considered one of the most important concepts in the 21th century. In the period of CALS, the roles of telecommunication companies are much important. In this paper, we present some tasks which should be done by telecommunication companies to prepare for CALS period. They are: development of virtual enterprise prototype, providing teleconference tool, execution of BPR, development of customer management system.
Primary Gastric Choriocarcinoma: Two Case Reports and Review of the Literatures
윤정호,김민수,국은희,안세환,전세용,한민성,허정권,강혜진,나임일,조수연,김상범,류백렬,양성현 대한암학회 2008 Cancer Research and Treatment Vol.40 No.3
Primary gastric choriocarcinoma (PGC) is a rare tumor, and its pathogenesis is still uncertain. Most PGCs have been reported to possess an adenocarcinoma component of variable extent, and pure PGC is especially rare. The diagnosis of PGC is confirmed by exhibition of choriocarcinomatous components on biopsy and exhibition of β-hCG positive cell on immunohistochemical stain and elevation of the serum β-hCG. Moreover it must be confirmed that no other site including gonads displays any tumor masses. The PGC tends to be more invasive and to have early metastasis. The median survival is known to be less than several months. We report two cases. The first case was a 62 year-old man who was diagnosed as advanced gastric cancer (AGC) by endoscopic biopsy with hepatic metasasis and received palliative chemotherapy with modified FOLFOX regimen and Genexol plus cisplatin regimen. He underwent subtotal gastrectomy due to perforation of the stomach during chemotherapy. On post-operative biopsy, He was re-diagnosed as PGC and received another palliative chemotherapy modified FOLFIRI, BEP, EMACO, VIP. However, multiple liver metastases were aggravated, and also serum AFP level increased. Ultimately, the paient died 10 months after initial diagnosis. Another case was a 45 year-old man. On endoscopic biopsy, he was diagnosed as AGC of adenocarcinoma. On Chest and Abdomen CT, multiple pulmonary and hepatic metastasis were also confirmed. On liver biopsy, He was diagnosed as PGC. The immunohistochemical stains were performed and the results were cytokeratin positive, EMA negative and β-hCG weak positive. The serum β-hCG level was highly elevated. BEP, VIP and EMA/CO combination therapy were administered, but he died at 12th months after the initial diagnosis.
소세포폐암에서 항암화학요법 중 발생한 치명적 종양용해증후군
국은희 ( Eun Hee Kook ),김민수 ( Min Soo Kim ),안세한 ( Se Han Ahn ),전세용 ( Se Young Jeon ),윤정호 ( Jung Ho Yoon ),한민성 ( Min Sung Han ),김철현 ( Cheol Hyeon Kim ),이재철 ( Jae Cheol Lee ) 대한결핵 및 호흡기학회 2008 Tuberculosis and Respiratory Diseases Vol.64 No.3
Tumor lysis syndrome is a life-threatening complication of anti-cancer therapy that typically occurs in patients with large, rapidly growing and treatment-sensitive tumors such as high-grade lymphomas and acute leukemias. However, its incidence in solid tumors has been known to be very low. Tumor lysis syndrome in solid tumors has a high mortality rate owing to the lack of prophylactic therapy to prevent this complication. We report a case of fatal tumor lysis syndrome developed during chemotherapy in extensive-stage small cell lung cancer, along with a brief review of the relevant literature considering the rarity of this manifestation in solid tumor. (Tuberc Respir Dis 2008;64:215-218)
증례 : 류마티스 ; 종양으로 오인될 수 있는 결절성 근육 유육종증 1예
안세한 ( Se Han Ahn ),김민수 ( Min Su Kim ),한민성 ( Min Sung Han ),윤정호 ( Jung Ho Yoon ),국은희 ( Eun Hee Kook ),전세용 ( Se Yong Jeon ),김철현 ( Cheol Hyeon Kim ) 대한내과학회 2011 대한내과학회지 Vol.80 No.2
The nodular form of muscular sarcoidosis is a rare malady that is often confused with a soft-tissue neoplasm or other lesion. Here, we present a case of nodular muscular sarcoidosis in the arms and legs of a 59-year-old woman. She presented at our hospital with a painless nodule in her left arm. Excision was performed and she was diagnosed with sarcoidosis. One year later, nodular sarcoidosis recurred in her arms and legs. After 2 months of steroid medication, the nodules disappeared. The patient has been followed for 2 years and no evidence of recurrence has been observed. (Korean J Med 2011;80:247-249)